Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
Files
Publication date
2019-12-26
Authors
Driehuis, Else
van Hoeck, Arne
Moore, Kat
Kolders, Sigrid
Francies, Hayley E.
Gulersonmez, Can M C
Stigter, Edwin Ca
Burgering, Boudewijn
Geurts, Veerle
Gracanin, Ana
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.
Keywords
Biobank, Cancer, Organoids, Pancreatic cancer, Personalized medicine, General, Journal Article
Citation
Driehuis, E, Van Hoeck, A, Moore, K, Kolders, S, Francies, H E, Gulersonmez, M C, Stigter, E C A, Burgering, B, Geurts, V, Gracanin, A, Bounova, G, Morsink, F H, Vries, R, Boj, S, Van Es, J, Offerhaus, G J A, Kranenburg, O, Garnett, M J, Wessels, L, Cuppen, E, Brosens, L A A & Clevers, H 2019, 'Pancreatic cancer organoids recapitulate disease and allow personalized drug screening', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 52, pp. 26580-26590. https://doi.org/10.1073/pnas.1911273116